logo

For the Inventor, By the Inventor

Marburg, Germany

Csl Behring Gmbh


USPTO Granted Patents = 74



Trademarks = 124

Forward Citations = 415

Loading Chart...
Loading Chart...

121 inventors (with patents filed for the assignee):

goldMedal Stefan Schulte (17 out of 30 patents)

silverMedal Marc Nolte (13 out of 23 patents)

bronzeMedal Thomas Weimer (13 out of 27 patents)

4.  Hubert Metzner (11 out of 28 patents)

5.  Gerhard Dickneite (8 out of 29 patents)

6.  Scott M Kee (7 out of 7 patents)

7.  Paul I Cook (7 out of 8 patents)

8.  James R Smith (7 out of 7 patents)

9.  Robert Kling (7 out of 7 patents)

10.  Scott A Fowler (7 out of 9 patents)

11.  David A Weber (7 out of 34 patents)

12.  Hans-Arnold Stoehr (7 out of 12 patents)

13.  Wiegand Lang (7 out of 11 patents)

14.  Annette Feussner (7 out of 18 patents)

15.  Stefan Schmidbauer (6 out of 7 patents)


Core Competencies:
Factor XII Inhibitors
Alpha-1-Antitrypsin Compositions
Coagulation Factor Replacement
Immunoglobulin Combination Therapy
Hydrophobic Charge Induction Chromatography
Therapeutic Proteins Purification
Von Willebrand Factor Variants
Remote Ischemia-Reperfusion Injury
Nucleic Acids Encoding Monoclonal Antibodies
Sulfated Glycosaminoglycans
Chronic Nephropathies Treatment
Neurotraumatic Disorder Therapy

74 patents:

1. D1070201 - Wash carriage rack (2025-04-08),
2. 12065481 - Therapy using a factor XII inhibitor in a neurotraumatic disorder (2024-08-20),
3. 11857610 - Methods for reducing risk of onset of acute graft versus host disease after hematopoietic cell transplantation (2024-01-02),
4. 11744880 - Blood coagulation factor replacement product for use in the treatment or prophylaxis of bleedings (2023-09-05),
5. 11554156 - Pharmaceutical formulations of C1 esterase inhibitor (2023-01-17),
6. 11426680 - Hydrophobic charge induction chromatographic protein depleted solution (2022-08-30),
7. 11345759 - Methods of administering inhibitory anti-factor XII/XIIa monoclonal antibodies (2022-05-31),
8. 11224643 - Methods of treatment using alpha-1-antitrypsin compositions (2022-01-18),
9. 10973891 - Treatment and prevention of remote ischemia-reperfusion injury (2021-04-13),
10. 10513560 - Methods of administering inhibitory anti-factor XII/XIIA monoclonal antibodies (2019-12-24),
11. 10471142 - Combination therapy using immunoglobulin and C1-Inhibitor (2019-11-12),
12. 10441631 - Therapeutic agent for amniotic fluid embolism (2019-10-15),
13. 10335467 - Methods of treatment using alpha-1-antitrypsin compositions (2019-07-02),
14. 10286047 - Treatment and prevention of remote ischemia-reperfusion injury (2019-05-14),
15. 10232015 - Sugar compositions for treating hemophilia A and/or Von Willebrand disease (2019-03-19),
CSL Behring is a global biopharmaceutical company that specializes in developing and manufacturing therapies for rare and serious diseases. With a focus on plasma-derived and recombinant therapies, CSL Behring aims to improve the lives of patients with conditions such as hemophilia, primary immune deficiencies, and hereditary angioedema. The company is committed to innovation, scientific research, and delivering quality products to patients worldwide.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 23 2025

...
74 Patents

#5 in Marburg

#790 in Germany

#9,715 in the World

...
Marburg, Germany

Csl Behring Gmbh

Forward Citations = 415

121 inventors:

goldMedal Stefan Schulte (17 out of 30 patents)

silverMedal Marc Nolte (13 out of 23 patents)

bronzeMedal Thomas Weimer (13 out of 27 patents)

4.  Hubert Metzner (11 out of 28 patents)

5.  Gerhard Dickneite (8 out of 29 patents)

Please report any incorrect information to support@idiyas.com
Loading…